^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AGEN2373

    i
    Other names: AGEN2373
    Associations

    News

    Trials
    Company:
    Agenus, Gilead
    Drug class:
    CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    1m
    Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=67, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting | N=200 --> 67
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    botensilimab (AGEN1181) • AGEN2373
    over2years
    Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patient With Advanced Cancer (clinicaltrials.gov)
    P1, N=200, Recruiting, Agenus Inc. | N=86 --> 200 | Trial completion date: Dec 2024 --> Jun 2027 | Trial primary completion date: Sep 2023 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    botensilimab (AGEN1181) • AGEN2373